High-performance Uncertainty Quantification in Large-scale Virtual Clinical Trials of Closed-loop Diabetes Treatment
Authors:
Asbjørn Thode Reenberg,
Tobias K. S. Ritschel,
Bernd Dammann,
John Bagterp Jørgensen
Abstract:
In this paper, we propose a virtual clinical trial for assessing the performance and identifying risks in closed-loop diabetes treatments. Virtual clinical trials enable fast and risk-free tests of many treatment variations for large populations of fictive patients (represented by mathematical models). We use closed-loop Monte Carlo simulation, implemented in high-performance software and hardware…
▽ More
In this paper, we propose a virtual clinical trial for assessing the performance and identifying risks in closed-loop diabetes treatments. Virtual clinical trials enable fast and risk-free tests of many treatment variations for large populations of fictive patients (represented by mathematical models). We use closed-loop Monte Carlo simulation, implemented in high-performance software and hardware, to quantify the uncertainty in treatment performance as well as to compare the performance in different scenarios or of different closed-loop treatments. Our software can be used for testing a wide variety of control strategies ranging from heuristical approaches to nonlinear model predictive control. We present an example of a virtual clinical trial with one million patients over 52 weeks, and we use high-performance software and hardware to conduct the virtual trial in 1 h and 22 min.
△ Less
Submitted 28 February, 2022;
originally announced February 2022.
A one-size-fits-all artificial pancreas for people with type 1 diabetes based on physiological insight and feedback control
Authors:
Tobias K. S. Ritschel,
Asbjørn Thode Reenberg,
Emilie B. Lindkvist,
Christian Laugesen,
Jannet Svensson,
Ajenthen G. Ranjan,
Kirsten Nørgaard,
Bernd Dammann,
John Bagterp Jørgensen
Abstract:
We propose a model-free artificial pancreas (AP) for people with type 1 diabetes. The algorithmic parameters are tuned to a virtual population of 1,000,000 individuals, and the AP repeatedly estimates the basal and bolus insulin requirements necessary for maintaining normal blood glucose levels. Therefore, the AP can be used without healthcare personnel or engineers customizing the algorithm to ea…
▽ More
We propose a model-free artificial pancreas (AP) for people with type 1 diabetes. The algorithmic parameters are tuned to a virtual population of 1,000,000 individuals, and the AP repeatedly estimates the basal and bolus insulin requirements necessary for maintaining normal blood glucose levels. Therefore, the AP can be used without healthcare personnel or engineers customizing the algorithm to each user. The estimates are based on bodyweight, measurements from a continuous glucose monitor (CGM), and estimates of the meal carbohydrate contents. In a virtual clinical trial with all 1,000,000 individuals (i.e., a Monte Carlo closed-loop simulation), the AP achieves a mean time in range of more than 87% and almost 89% of the participants satisfy several glycemic targets.
△ Less
Submitted 27 February, 2022;
originally announced February 2022.
